Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Simponi (golimumab by Quarter
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)
Merck Simponi (golimumab: $0M in Q4 2025, down 100.0% from a year earlier. That is the lowest of the 40 quarters on record here.
Where the Q4 2025 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up simponi (golimumab
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M)0 · Q4 2025
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — International sales ($M)0 · Q4 2025
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)-4.0% · Q2 2024
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%)-24.0% · Q4 2024
Cite this data
StockData. (2026). Merck Simponi (golimumab ($M), quarterly Q1 2016–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-simponi
See every metric in the Merck KPI table. Data updated Oct 26, 2026.